Intravenous Immunoglobulin Market Size is valued at USD 13.26 billion in 2024 and is predicted to reach USD 25.46 billion by the year 2034 at a 7.0% CAGR during the forecast period for 2025-2034.
Immunoglobulins are glycoprotein molecules produced by plasma or white blood cells. Immunoglobulins serve as a crucial line of defense for the immune system, recognizing and attaching to certain antigens such as bacteria and viruses and aiding in their elimination. Intravenous immunoglobulins are immunoglobulins that are delivered intravenously. Because most patients getting immunoglobulins are in hospitals or clinical settings, intravenous immunoglobulins are the most commonly used mode of administration. This, along with the immunoglobulins' demonstrated efficacy as an effective therapy choice for various immunological illnesses and a lack of training for homecare settings, is driving the Intravenous Immunoglobulin market expansion.
However, tight government rules regarding the use of intravenous immunoglobulin products and the significant risk of side effects associated with them are projected to hamper market expansion. On the contrary, the widespread use of intravenous immunoglobulin for treating various disorders is projected to open up profitable opportunities shortly.
The Intravenous Immunoglobulin market is segmented into therapeutic area, dosage form, type of immunoglobulin, end user. based on the therapeutic area, the market is segmented into primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barre syndrome (GBS), immune thrombocytopenic purpura (ITP), multifocal motor neuropathy (MMN). The market is segmented by dosage form into liquid and lyophilized. The market is segmented by type of immunoglobulin into IgG, IgA, IgM, IgE, and IgD. The market is segmented by end users into hospitals, clinics, homecare and other end users.
The hospital segment is projected to grow rapidly in the global Intravenous Immunoglobulin market because of the extensive hospital network. Furthermore, the rising prevalence of primary immunological deficiencies, hepatitis C, and other disorders has increased the frequency of hospitalizations worldwide, increasing customer demand. Furthermore, hospitals provide prompt reimbursement, treatment, and proper care to many patients, expanding the number of patients.
The North America Intravenous Immunoglobulin market is expected to register the highest market share in revenue shortly. The major factors driving market expansion are the rising level of awareness about goods used to treat immunodeficiency illnesses, expanding clinician interest in these medicines, and rising healthcare expenditure.
Furthermore, the increasing use of IVIG therapies for illness treatment, established healthcare and research infrastructure, and the rapidly growing number of product approvals from the US FDA are expected to contribute to the region's revenue growth. In addition, Asia Pacific is projected to raise at a rapid rate in the global Intravenous Immunoglobulin market due to Emerging economies, rising healthcare spending, and a fast-expanding immunoglobulin market are all factors to consider.
| Report Attribute | Specifications |
| Market size value in 2024 | USD 13.26 Bn |
| Revenue Forecast in 2034 | USD 25.46 Bn |
| Growth rate CAGR | CAGR of 7.0% from 2025 to 2034 |
| Quantitative units | Representation of revenue in US$ million and CAGR from 2024 to 2031 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends |
| Segments Covered | By Therapeutic Area, By Dosage Form, By Type of Immunoglobulin, By End User and By Region |
| Regional scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; Southeast Asia |
| Competitive Landscape | Biotest AG, Octapharma AG, LFB Biotechnologies, Grifols SA, CSL Behring, China Biologics Products Inc., Kedrion Biopharma, BDI Pharma Inc., Shanghai RAAS Blood products, Shire and Others |
| Customization scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and available payment methods | Explore pricing alternatives that are customized to your particular study requirements. |
Intravenous Immunoglobulin Market- By Therapeutic Area
Intravenous Immunoglobulin Market- By Dosage Form
Intravenous Immunoglobulin Market- By Immunoglobulin
Intravenous Immunoglobulin Market- By End User
Intravenous Immunoglobulin Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Rest of Middle East and Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Intravenous Immunoglobulin Market Snapshot
Chapter 4. Global Intravenous Immunoglobulin Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Therapeutic Area Estimates & Trend Analysis
5.1. by Therapeutic Area & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Therapeutic Area:
5.2.1. Primary Immunodeficiency
5.2.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.2.3. Guillain-Barré Syndrome (GBS)
5.2.4. Immune Thrombocytopenic Purpura (ITP)
5.2.5. Multifocal Motor Neuropathy (MMN)
Chapter 6. Market Segmentation 2: by Dosage Form Estimates & Trend Analysis
6.1. by Dosage Form & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Dosage Form:
6.2.1. Liquid
6.2.2. Lyophilized
Chapter 7. Market Segmentation 3: by Immunoglobulin Estimates & Trend Analysis
7.1. by Immunoglobulin & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Immunoglobulin:
7.2.1. IgG
7.2.2. IgA
7.2.3. IgM
7.2.4. IgE
7.2.5. IgD
Chapter 8. Market Segmentation 4: by End User Estimates & Trend Analysis
8.1. by End User & Market Share, 2024 & 2034
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by End User:
8.2.1. Hospitals
8.2.2. Clinics
8.2.3. Homecare
8.2.4. Other End Users
Chapter 9. Intravenous Immunoglobulin Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
9.1.2. North America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Dosage Form, 2021-2034
9.1.3. North America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Type of Immunoglobulin, 2021-2034
9.1.4. North America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.1.5. North America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.2. Europe
9.2.1. Europe Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
9.2.2. Europe Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Dosage Form, 2021-2034
9.2.3. Europe Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Type of Immunoglobulin, 2021-2034
9.2.4. Europe Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.2.5. Europe Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.3. Asia Pacific
9.3.1. Asia Pacific Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
9.3.2. Asia Pacific Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Dosage Form, 2021-2034
9.3.3. Asia-Pacific Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Type of Immunoglobulin, 2021-2034
9.3.4. Asia-Pacific Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.3.5. Asia Pacific Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.4. Latin America
9.4.1. Latin America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
9.4.2. Latin America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Dosage Form, 2021-2034
9.4.3. Latin America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Type of Immunoglobulin, 2021-2034
9.4.4. Latin America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.4.5. Latin America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.5. Middle East & Africa
9.5.1. Middle East & Africa Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
9.5.2. Middle East & Africa Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Dosage Form, 2021-2034
9.5.3. Middle East & Africa Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Type of Immunoglobulin, 2021-2034
9.5.4. Middle East & Africa Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.5.5. Middle East & Africa Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Bio Products Laboratory
10.2.2. Biotest
10.2.3. China biologics Products Holdings
10.2.4. CSL Behring
10.2.5. Grifols
10.2.6. Kedrion
10.2.7. LFB
10.2.8. Octapharma
10.2.9. Shanghai RAAS Blood products
10.2.10. Shire
10.2.11. Other Prominent Players